Ono Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016

Published: Oct, 2016 | Pages: 118 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Ono Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Ono Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016', provides an overview of the Ono Pharmaceutical Co., Ltd.'s pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Ono Pharmaceutical Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Ono Pharmaceutical Co., Ltd.
- The report provides overview of Ono Pharmaceutical Co., Ltd. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Ono Pharmaceutical Co., Ltd.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Ono Pharmaceutical Co., Ltd.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate Ono Pharmaceutical Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Ono Pharmaceutical Co., Ltd.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Ono Pharmaceutical Co., Ltd.'s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 6
Ono Pharmaceutical Co., Ltd. Snapshot 7
Ono Pharmaceutical Co., Ltd. Overview 7
Key Facts 7
Ono Pharmaceutical Co., Ltd. - Research and Development Overview 8
Key Therapeutic Areas 8
Ono Pharmaceutical Co., Ltd. - Pipeline Review 13
Pipeline Products by Stage of Development 13
Pipeline Products - Monotherapy 14
Pipeline Products - Combination Treatment Modalities 15
Pipeline Products - Partnered Products 16
Partnered Products/Combination Treatment Modalities 17
Pipeline Products - Out-Licensed Products 18
Out-Licensed Products/Combination Treatment Modalities 19
Ono Pharmaceutical Co., Ltd. - Pipeline Products Glance 20
Ono Pharmaceutical Co., Ltd. - Late Stage Pipeline Products 20
Pre-Registration Products/Combination Treatment Modalities 20
Phase III Products/Combination Treatment Modalities 21
Ono Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products 22
Phase II Products/Combination Treatment Modalities 22
Phase I Products/Combination Treatment Modalities 23
Ono Pharmaceutical Co., Ltd. - Early Stage Pipeline Products 24
Preclinical Products/Combination Treatment Modalities 24
Discovery Products/Combination Treatment Modalities 25
Ono Pharmaceutical Co., Ltd. - Drug Profiles 26
(carbidopa + levodopa prodrug) - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
abatacept - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
anamorelin hydrochloride - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
E-0001163 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
etelcalcetide hydrochloride - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
ivabradine hydrochloride - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
landiolol - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
metyrosine - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Monoclonal Antibody for Autoimmune Disease - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
nivolumab - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
ONO-2952 - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
ONO-4059 - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
ONO-4127 - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
ONO-4232 - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
ONO-4310321 - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
ONO-4474 - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
ONO-7268MX1 - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
ONO-7268MX2 - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
ONO-8055 - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
ONO-8430506 - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
ONO-8577 - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
opicapone - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
oprozomib - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
salirasib - Drug Profile 94
Product Description 94
Mechanism Of Action 94
R&D Progress 94
Small Molecule to Antagonize S1P2 - Drug Profile 96
Product Description 96
Mechanism Of Action 96
R&D Progress 96
Small Molecule to Inhibit Protease Enzyme for Undisclosed Indication - Drug Profile 97
Product Description 97
Mechanism Of Action 97
R&D Progress 97
Small Molecules to Antagonize Lysophosphatidic Acid Receptor 1 - Drug Profile 98
Product Description 98
Mechanism Of Action 98
R&D Progress 98
Ono Pharmaceutical Co., Ltd. - Pipeline Analysis 99
Ono Pharmaceutical Co., Ltd. - Pipeline Products by Target 99
Ono Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration 102
Ono Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type 103
Ono Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action 104
Ono Pharmaceutical Co., Ltd. - Dormant Projects 107
Ono Pharmaceutical Co., Ltd. - Discontinued Pipeline Products 109
Discontinued Pipeline Product Profiles 111
arundic acid 111
asimadoline 111
ceralifimod 111
freselestat 111
gemilukast 111
ipilimumab 111
limaprost 111
methylnaltrexone bromide 112
NIP-022 112
ONO-1266 112
ONO-2506-PO 112
ONO-4053 112
ONO-4127 112
ONO-5129 112
ONO-5334 112
ONO-6126 113
ONO-8539 113
remimazolam 113
rivenprost 113
tecemotide 113
Ono Pharmaceutical Co., Ltd. - Locations And Subsidiaries 114
Head Office 114
Other Locations & Subsidiaries 115

Appendix 117
Methodology 117
Coverage 117
Secondary Research 117
Primary Research 117
Expert Panel Validation 117
Contact Us 117
Disclaimer 118

List of Tables

Ono Pharmaceutical Co., Ltd., Key Facts 7
Ono Pharmaceutical Co., Ltd. - Pipeline by Indication, 2016 10
Ono Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2016 13
Ono Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2016 14
Ono Pharmaceutical Co., Ltd. - Combination Treatment Modalities in Pipeline, 2016 15
Ono Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2016 16
Ono Pharmaceutical Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2016 17
Ono Pharmaceutical Co., Ltd. - Out-Licensed Products in Pipeline, 2016 18
Ono Pharmaceutical Co., Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2016 19
Ono Pharmaceutical Co., Ltd. - Pre-Registration, 2016 20
Ono Pharmaceutical Co., Ltd. - Phase III, 2016 21
Ono Pharmaceutical Co., Ltd. - Phase II, 2016 22
Ono Pharmaceutical Co., Ltd. - Phase I, 2016 23
Ono Pharmaceutical Co., Ltd. - Preclinical, 2016 24
Ono Pharmaceutical Co., Ltd. - Discovery, 2016 25
Ono Pharmaceutical Co., Ltd. - Pipeline by Target, 2016 100
Ono Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2016 102
Ono Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2016 103
Ono Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2016 105
Ono Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2016 107
Ono Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2016 109
Ono Pharmaceutical Co., Ltd., Other Locations 115
Ono Pharmaceutical Co., Ltd., Subsidiaries 116